Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenetic Biosciences (XBIO) Cash from Operations (2023 - 2025)

Xenetic Biosciences' Cash from Operations history spans 7 years, with the latest figure at 242682.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 63.99% year-over-year to 242682.0; the TTM value through Dec 2025 reached 2286651.0, up 18.84%, while the annual FY2025 figure was 2286651.0, 18.84% up from the prior year.
  • Cash from Operations reached 242682.0 in Q4 2025 per XBIO's latest filing, up from 658247.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 242682.0 in Q4 2025 to a low of 1269120.0 in Q2 2023.
  • Average Cash from Operations over 3 years is 768195.67, with a median of 733509.5 recorded in 2023.
  • The largest YoY upside for Cash from Operations was 63.99% in 2025 against a maximum downside of 43.4% in 2025.
  • A 3-year view of Cash from Operations shows it stood at 793027.0 in 2023, then grew by 15.01% to 673992.0 in 2024, then soared by 63.99% to 242682.0 in 2025.
  • Per Business Quant, the three most recent readings for XBIO's Cash from Operations are 242682.0 (Q4 2025), 658247.0 (Q3 2025), and 383830.0 (Q2 2025).